References
- Dewey WC, Hopwood LE, Sapareto SA, Gerweck LE. (1977). Cellular responses to combinations of hyperthermia and radiation. Radiology 123:463–74.
- Sapareto SA, Hopwood LE, Dewey WC. (1978). Combined effects of X-irradiation and hyperthermia on CHO cells for various temperatures and orders of application. Radiat Res 73:221–33.
- Overgaard J, Gonzalez Gonzalez D, Hulshof MC, et al. (1995). Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. Lancet 345:540–3.
- Harima Y, Nagata K, Harima K, et al. (2001). A randomized clinical trial of radiation therapy versus thermoradiotherapy in stage IIIB cervical carcinoma. Int J Hyperthermia 17:97–105.
- Vernon CC, Hand JW, Field SB, et al. (1996). Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. Int J Radiat Oncol Biol Phys 35:731–44.
- Sneed PK, Stauffer PR, McDermott MW, et al. (1998). Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/− hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Biol Phys 40:287–95.
- Wust P, Hildebrandt B, Sreenivasa G, et al. (2002). Hyperthermia in combined treatment of cancer. Lancet Oncol 3:487–97.
- Datta NR, Ordonez SG, Gaipl US, et al. (2015). Local hyperthermia combined with radiotherapy and-/or chemotherapy: recent advances and promises for the future. Cancer Treat Rev 41:742–53.
- Issels RD, Abdel-Rahman S, Wendtner C, et al. (2001). Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study. Eur J Cancer 37:1599–608.
- Falk MH, Issels RD. (2001). Hyperthermia in oncology. Int J Hyperthermia 17:1–18.
- Song CW. (1984). Effect of local hyperthermia on blood flow and microenvironment: a review. Cancer Res 44:4721s–40s.
- Kang MS, Song CW, Levitt SH. (1980). Role of vascular function in response of tumors in vivo to hyperthermia. Cancer Res 40:1130–5.
- Iwata K, Shakil A, Hur WJ, et al. (1996). Tumour pO2 can be increased markedly by mild hyperthermia. Br J Cancer Suppl 27:S217–21.
- Song CW, Park HJ, Lee CK, Griffin R. (2005). Implications of increased tumor blood flow and oxygenation caused by mild temperature hyperthermia in tumor treatment. Int J Hyperthermia 21:761–7.
- Vujaskovic Z, Song CW. (2004). Physiological mechanisms underlying heat-induced radiosensitization. Int J Hyperthermia 20:163–74.
- Song CW, Shakil A, Osborn JL, Iwata K. (2009). Tumour oxygenation is increased by hyperthermia at mild temperatures. Int J Hyperthermia 25:91–5.
- Dewhirst MW, Vujaskovic Z, Jones E, Thrall D. (2005). Re-setting the biologic rationale for thermal therapy. Int J Hyperthermia 21:779–90.
- Brizel DM, Scully SP, Harrelson JM, et al. (1996). Radiation therapy and hyperthermia improve the oxygenation of human soft tissue sarcomas. Cancer Res 56:5347–50.
- Evans SS, Wang WC, Bain MD, et al. (2001). Fever-range hyperthermia dynamically regulates lymphocyte delivery to high endothelial venules. Blood 97:2727–33.
- Frey B, Weiss EM, Rubner Y, et al. (2012). Old and new facts about hyperthermia-induced modulations of the immune system. Int J Hyperthermia 28:528–42.
- Repasky EA. (2013). Progress in development of biomedical applications of heat shock proteins and thermal stress. Int J Hyperthermia 29:359–61.
- Repasky EA, Evans SS, Dewhirst MW. (2013). Temperature matters! And why it should matter to tumor immunologists. Cancer Immunol Res 1:210–16.
- Evans SS, Repasky EA, Fisher DT. (2015). Fever and the thermal regulation of immunity: the immune system feels the heat. Nat Rev Immunol 15:335–49.
- Kavanagh BD. (2014). Stereotactic body radiation therapy as a derivative of stereotactic radiosurgery: clinically independent but with enduring common themes. J Clin Oncol 32:2827–31.
- Timmerman RD, Herman J, Cho LC. (2014). Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice. J Clin Oncol 32:2847–54.
- Nagata Y. (2013). Stereotactic body radiotherapy for early stage lung cancer. Cancer Res Treat 45:155–61.
- Jang WI, Kim MS, Bae SG, et al. (2013). High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma. Radiat Oncol 8:250.
- Park HJ, Griffin RJ, Hui S, et al. (2012). Radiation-induced vascular damage in tumors: implication of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res 177:311–27.
- Song CW, Kim MS, Cho LC, et al. (2014). Radiobiological basis of SBRT and SRS. Int J Clin Oncol 19:570–8.
- Kim MS, Kim W, Park IH, et al. (2015). Radiobiological mechanisms of stereotactic body radiation therapy and stereotactic radiation surgery. Radiat Oncol J 33:265–75.
- Song CW, Lee YJ, Griffin RJ, et al. (2015). Indirect tumor cell death after high-dose hypofractionated irradiation: implications for stereotactic body radiation therapy and stereotactic radiation surgery. Int J Radiat Oncol Biol Phys 93:166–72.
- Solesvik OV, Rofstad EK, Brustad T. (1984). Vascular changes in a human malignant melanoma xenograft following single-dose irradiation. Radiat Res 98:115–28.
- El Kaffas A, Gilles A, Czarnota GJ. (2013). Dose-dependent response of tumor vasculature to radiation therapy in combination with Sunitinib depicted by three-dimensional high-frequency power Doppler ultrasound. Angiogenesis 16:443–54.
- Maeda A, Chen Y, Bu J, et al. (2017). In vivo imaging reveals significant tumor vascular dysfunction and increased tumor hypoxia-inducible factor-1α expression induced by high single-dose irradiation in a pancreatic tumor model. Int J Radiat Oncol Biol Phys 97:184–94.
- Harada H, Inoue M, Itasaka S, et al. (2012). Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels. Nat Commun 3:783.
- Moeller BJ, Cao Y, Li CY, Dewhirst MW. (2004). Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5:429–41.
- Mimeault M, Batra SK. (2013). Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J Cell Mol Med 17:30–54.
- Semenza GL. (1998). Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr Opin Genet Dev 8:588–94.
- Kim YH, Yoo KC, Cui YH, et al. (2014). Radiation promotes malignant progression of glioma cells through HIF-1alpha stabilization. Cancer Lett 354:132–41.
- Zhang M, Qui Q, Li Z, et al. (2015). HIF-1alpha regulate the response of primary sarcomas to radiation therapy through a cell autonomous mechanisms. Radiat Res 183:594–609.
- Barker HE, Paget JT, Khan AA, Harrington KJ. (2015). The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer 15:409–25.
- Tepeköylü C, Wang FS, Kozaryn R, et al. (2013). Shock wave treatment induces angiogenesis and mobilizes endogenous CD31/CD34-positive endothelial cells in a hindlimb ischemia model: implications for angiogenesis and vasculogenesis. J Thorac Cardiovasc Surg 146:971–8.
- Rankin EB, Giaccia AJ. (2016). Hypoxic control of metastasis. Science 352:175–80.
- Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. (2004). Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10:858–64.
- Maxwell PH, Wiesener MS, Chang GW, et al. (1999). The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271–5.
- Ohh M, Park CW, Ivan M, et al. (2000). Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel–Lindau protein. Nat Cell Biol 2:423–7.
- Jeon TW, Yang H, Lee CG, et al. (2016). Electro-hyperthermia up-regulates tumour suppressor septin 4 to induce apoptotic cell death in hepatocellular carcinoma. Int J Hyperthermia 32:648–56.
- Hegyi G, Szasz O, Szasz A. (2009). Oncothermia treatment of cancer: from the laboratory to clinic. Electromagn Biol Med 28:148–65.
- Hegyi G, Szigeti GP, Szasz A. (2013). Hyperthermia versus oncothermia: cellular effects in complementary cancer therapy. Evid Based Complement Alternat Med 2013:672873.
- Kim W, Seong J, An JH, Oh HJ. (2007). Enhancement of tumor radioresponse by wortmannin in C3H/HeJ hepatocarcinoma. J Radiat Res 48:187–95.
- Kim W, Seong J, Oh HJ, et al. (2011). A novel combination treatment of armed oncolytic adenovirus expressing IL-12 and GM-CSF with radiotherapy in murine hepatocarcinoma. J Radiat Res 52:646–54.
- Dings RP, Loren M, Heum H, et al. (2007). Scheduling of radiation with angiogenesis inhibitors anginex and Vastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 13:3395–402.
- Moon EJ, Sonveaux P, Porporato PE, et al. (2010). NADPH oxidase-mediated reactive oxygen species production activates hypoxia-inducible factor-1 (HIF-1) via the ERK pathway after hyperthermia treatment. PNAS 107:20477–82.
- Ke S, Ding XM, Kong J, et al. (2010). Low temperature of radiofrequency ablation at the target sites can facilitate rapid progression of residual hepatic VX2 carcinoma. J Transl Med 8:73.